France's Diatos has moved into a new 800m2 office and laboratory space in Paris Biopark, more than double the size of the firm's current facilities.
The new site includes offices and laboratories able to accommodate all Diatos's employees and will set the company up to progress its research programs in cellular-delivery and drug-targeting The company has equipped its new research laboratories with state of the art equipment, including a new chemistry lab with organic and analytical chemistry and a P2-grade cell culture room.
Founded in 1999 as a spin-off from France's Institut Pasteur, Diatos is developing two drug delivery platforms. The first is its Diatos Peptide Vector (DPV) technology, designed to allow cellular or nuclear uptake of a range of therapeutic agents, while the second, known as Tumour-Selective Prodrug (TSP), provides for the release of anticancer drugs at the tumour site.